Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2010

Open Access 01-12-2010 | Erratum

Erratum to: A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy

Authors: Chun Hei Antonio Cheung, Xueying Sun, Jagat R Kanwar, Ji-Zhong Bai, LiTing Cheng, Geoffrey W Krissansen

Published in: Cancer Cell International | Issue 1/2010

Login to get access

Excerpt

Since publication of our article [1], we have regrettably noticed an error. The molarities of 16, 48, 80 and 112 μg/mL solutions of dNSurR9-C84A of molecular weight 42 kDa were incorrectly given as 1, 3, 5, and 7 μM. The correct molarities which should be used throughout are 0.38, 1.1, 1.9, and 2.7 μM, respectively. …
Literature
1.
Cheung Hei Antonio Chun, Sun Xueying, Kanwar Jagat, Bai Ji-Zhong, Cheng LiTing, Krissansen Geoffrey: A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell International. 2010, 10: 36-10.1186/1475-2867-10-36.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy
Authors
Chun Hei Antonio Cheung
Xueying Sun
Jagat R Kanwar
Ji-Zhong Bai
LiTing Cheng
Geoffrey W Krissansen
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2010
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-10-43

Other articles of this Issue 1/2010

Cancer Cell International 1/2010 Go to the issue

Primary research

Bradykinin increases resensitization of purinergic receptor signaling in glioma cells

Erratum

Erratum to: Transformation of SV40-immortalized human uroepithelial cells by 3-methylcholanthrene increases IFN- and Large T Antigen-induced transcripts

Primary research

A natural compound from Hydnophytum formicarium induces apoptosis of MCF-7 cells via up-regulation of Bax

Primary research

Identification and validation of genes involved in gastric tumorigenesis

Primary research

MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines

Primary research

Effects of myenteric denervation on extracellular matrix fibers and mast cell distribution in normal stomach and gastric lesions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits